drugset / Trial / NCT04552600
Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.
Phase 1/2
Completed
100 enrolled
Natureceuticals Sdn Bhd
Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia · collabMinistry of Agriculture, Malaysia · collabQuest International University, Malaysia. · collabUniversiti Sains Malaysia · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Diabetic retinopathy (DR) is a common complication of diabetes mellitus that leads to loss of vision and blindness among working age adults. An ideal adjunctive agent for treating DR hence should be polymorphic and possess antiangiogenic, neuroprotective, anti-inflammatory, anti-oxidant as well as anti-ischaemic properties.Natureceuticals Sdn Bhd assessed the efficacy of core ingredient of Nuvastatic™, Lanctos 75™ for the treatment and management of the diabetic retinopathic condition.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2022-08-10
- Completion
- 2022-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nuvastatic | Unknown | 1000 mg | Oral |